How Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story

Simply Wall St.04-28 21:07

Kiniksa Pharmaceuticals International reported Q1 2026 results on April 28, following a year in which annual revenue rose to US$677.56 million from US$423.24 million and the company moved from a net ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630588574?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-28 21:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630588574","market":"sg","top_or_hot":-1,"title":"How Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story","media":"Simply Wall St.","content":"<div>\n<p>Kiniksa Pharmaceuticals International reported Q1 2026 results on April 28, following a year in which annual revenue rose to US$677.56 million from US$423.24 million and the company moved from a net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-kiniksas-shift-to-profitability-and-higher-revenue-at-ki\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Kiniksa’s Shift To Profitability And Higher Revenue At Kiniksa Pharmaceuticals International (KNSA) Has Changed Its Investment Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-28 21:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-kiniksas-shift-to-profitability-and-higher-revenue-at-ki><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kiniksa Pharmaceuticals International reported Q1 2026 results on April 28, following a year in which annual revenue rose to US$677.56 million from US$423.24 million and the company moved from a net ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-kiniksas-shift-to-profitability-and-higher-revenue-at-ki\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-kiniksas-shift-to-profitability-and-higher-revenue-at-ki","article_id":"2630588574","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-knsa/kiniksa-pharmaceuticals-international/news/how-kiniksas-shift-to-profitability-and-higher-revenue-at-ki","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630588574","pubTimestamp":1777381652,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Kiniksa Pharmaceuticals International reported Q1 2026 results on April 28, following a year in which annual revenue rose to US$677.56 million from US$423.24 million and the company moved from a net loss to profitability.\nThis shift from loss-making to profitable operations, supported by continued R&D spending, marks a significant change in the company’s financial profile and capacity to fund its drug pipeline internally.\nWe’ll now examine how Kiniksa’s recent move to profitability and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"Kiniksa Pharmaceuticals International(KNSA)向盈利能力和更高收入的转变如何改变了其投资故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1.5},"content_text":"Kiniksa Pharmaceuticals International reported Q1 2026 results on April 28, following a year in which annual revenue rose to US$677.56 million from US$423.24 million and the company moved from a net loss to profitability. This shift from loss-making to profitable operations, supported by continued R&D spending, marks a significant change in the company’s financial profile and capacity to fund its drug pipeline internally. We’ll now examine how Kiniksa’s recent move to profitability and stronger revenue base may influence its existing investment narrative. AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.AdvertisementKiniksa Pharmaceuticals International Investment Narrative RecapTo be comfortable owning Kiniksa, you need to believe ARCALYST can keep expanding in recurrent pericarditis while the pipeline gradually reduces single‑drug reliance. The recent confirmation of profitability and a higher revenue base supports that view but does not materially change the biggest near term swing factor: how quickly ARCALYST penetration can grow versus the risk that competition, pricing pressure, or slower uptake curbs that momentum. The Q4 2025 earnings release, showing full year revenue rising to US$677.56 million and a move to US$59.01 million in net income, is the most relevant backdrop here. It highlights that Kiniksa’s ability to self fund R&D on assets like KPL‑387 now rests heavily on ARCALYST’s current strength, which cuts both ways for the core catalyst of continued uptake and the key risk of concentrated product exposure. Yet behind this profitability story, investors should also be aware of the growing risk that payer scrutiny and potential competition could... Read the full narrative on Kiniksa Pharmaceuticals International (it's free!)Kiniksa Pharmaceuticals International's narrative projects $992.0 million revenue and $189.0 million earnings by 2028.Uncover how Kiniksa Pharmaceuticals International's forecasts yield a $55.88 fair value, a 28% upside to its current price.Exploring Other PerspectivesKNSA 1-Year Stock Price Chart Some of the lowest ranked analysts were assuming Kiniksa would reach about US$937.3 million in revenue and US$135.1 million in earnings by 2028, but they still saw concentrated ARCALYST risk and tougher pricing as serious headwinds, which shows how differently you and other investors might interpret today’s profitability news and what it could mean for future updates to those forecasts.Explore 4 other fair value estimates on Kiniksa Pharmaceuticals International - why the stock might be worth over 4x more than the current price!Form Your Own VerdictDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Kiniksa Pharmaceuticals International research is our analysis highlighting 4 key rewards that could impact your investment decision.Our free Kiniksa Pharmaceuticals International research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Kiniksa Pharmaceuticals International's overall financial health at a glance.Ready For A Different Approach?Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Kiniksa Pharmaceuticals International might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630588574","isCrawlerRequest":true}